Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.3.1391

MiR-130a Overcomes Gefitinib Resistance by Targeting Met in Non-Small Cell Lung Cancer Cell Lines  

Zhou, Yong-Ming (Department of Geriatrics, Wuhan University, Renmin Hospital)
Liu, Juan (Department of Geriatrics, Wuhan University, Renmin Hospital)
Sun, Wei (Department of Thoracic Surgery, Tongji Hospital of Huazhong University of Science and Technology)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.3, 2014 , pp. 1391-1396 More about this Journal
Abstract
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the most common cause of lung cancer death. Currently, the epidermal growth factor receptor inhibitor gefitinib is used for its treatment; however, drug resistance is a major obstacle. Expression of Met has been associated with both primary and acquired resistance to gefitinib, but the mechanisms regulating its expression are not fully understood. Recently, miRNAs such as miR-130a have been shown to play a role in gefitinib resistance, but importance in NSCLC and relationships with Met have not been fully explored. Here we show that miR-130a is over-expressed in gefitinibsensitive NSCLC cell lines, but is low in gefitinib-resistant NSCLC cell lines. Moreover, miR-130a expression was negatively correlated with that of Met. Further analysis revealed that over-expression of miR-130a increased cell apoptosis and inhibited proliferation of NSCLC cells treated with gefitinib, whereas lowering the expression of miR-130a decreased cell apoptosis and promoted cell proliferation after treatment with gefitinib in both gefitinib-sensitive and -resistant NSCLC cell lines, suggesting that miR-130a overcomes gefitinib resistance. We also demonstrated that miR-130a binds to the 3'-UTR of Met and significantly suppresses its expression. Finally, our results showed that over-expressing Met could "rescue" the functions of miR-130a regarding cell apoptosis and proliferation after cells are treated with gefitinib. These findings indicate that the miR-130a/Met axis plays an important role in gefitinib resistance in NSCLC. Thus, the miR-130a/Met axis may be an effective therapeutic target in gefitinib-resistant lung cancer patients.
Keywords
miR -130a; gefitinib resistance; Met; NSCLC;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-1500.   DOI   ScienceOn
2 Pao W, Miller VA, Politi KA, et al (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2, e73.   DOI   ScienceOn
3 Ramachandran PV, Ignacimuthu S (2012). RNA Interference as a Plausible Anticancer Therapeutic Tool. Asian Pac J Cancer P, 13, 2445-52.   과학기술학회마을   DOI   ScienceOn
4 Sekido Y (2010). Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci, 101, 1-6.   DOI   ScienceOn
5 Sequist LV, Martins RG, Spigel D, et al (2008). First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol, 26, 2442-9.   DOI   ScienceOn
6 Suda K, Murakami I, Katayama T, et al (2010). Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res, 16, 5489-98.   DOI   ScienceOn
7 Xu N, Shen C, Luo Y, et al (2012). Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun, 425, 468-72.   DOI   ScienceOn
8 Yang F, Miao L, Mei Y, et al (2013). Retinoic acid-induced HOXA5 expression is co-regulated by HuR and miR-130a. Cell Signal, 25, 1476-85.   DOI   ScienceOn
9 Yang L, Li N, Wang H, et al (2012). Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep, 28, 592-600.
10 Kosaka T, Yatabe Y, Endoh H, et al (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res, 12, 5764-9.   DOI   ScienceOn
11 Gazdar AF (2009). Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene, 28 Suppl 1, S24-31.   DOI   ScienceOn
12 Guo A, Villen J, Kornhauser J, et al (2008). Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A, 105, 692-7.   DOI   ScienceOn
13 Kong YW, Ferland-McCollough D, Jackson TJ, et al (2012). microRNAs in cancer management. Lancet Oncol, 13, e249-58.   DOI   ScienceOn
14 Li H, Schmid-Bindert G, Wang D, et al (2011). Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci, 56, 275-84.   DOI   ScienceOn
15 Luo W, Huang B, Li Z, et al (2013). MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One, 8, e64759.   DOI
16 Matoulkova E, Michalova E, Vojtesek B, et al (2012). The role of the 3' untranslated region in post-transcriptional regulation of protein expression in mammalian cells. RNA Biol, 9, 563-76.   DOI   ScienceOn
17 Molina JR, Yang P, Cassivi SD, et al (2008). Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83, 584-94.   DOI
18 Mujahid S, Nielsen HC, Volpe MV (2013). MiR-221 and miR-130a regulate lung airway and vascular development. PLoS One, 8, e55911.   DOI
19 Acunzo M, Visone R, Romano G, et al (2012). miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene, 31, 634-42.
20 Oxnard GR, Miller VA (2010). Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park), 24, 392-9.
21 Belalcazar A, Azana D, Perez CA, et al (2012). Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther, 12, 519-28.   DOI   ScienceOn
22 Boll K, Reiche K, Kasack K, et al (2013). MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene, 32, 277-85.   DOI   ScienceOn
23 Burris HA, 3rd (2009). Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene, 28 Suppl 1, S4-13.   DOI   ScienceOn
24 Dimitroulis J, Stathopoulos GP (2005). Evolution of non-small cell lung cancer chemotherapy (Review). Oncol Rep, 13, 923-30.
25 Engelman JA, Zejnullahu K, Mitsudomi T, et al (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-43.   DOI   ScienceOn
26 Farazi TA, Spitzer JI, Morozov P, et al (2011). miRNAs in human cancer. J Pathol, 223, 102-15.   DOI   ScienceOn
27 Garofalo M, Romano G, Di Leva G, et al (2012). EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med, 18, 74-82.
28 Chen Y, Gorski DH (2008). Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood, 111, 1217-26.
29 Zhang W, Mendoza MC, Pei X, et al (2012). Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling. J Biol Chem, 287, 11850-8.   DOI   ScienceOn
30 Sandberg R, Neilson JR, Sarma A, et al (2008). Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites. Science, 320, 1643-7.   DOI   ScienceOn